This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information about Boehringer Ingelheim oncology.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that compound status or the registration status and approved product labels of the products described within this website may not be the same in different countries.
Information about approved products on this website is derived from the Summary of Product Characteristics (SPC) for each product in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and the United Kingdom and have read and understood this disclaimer.
This event has ended
We are dedicated to collaborating with the oncology community on a shared journey to deliver leading science.
To that end, Boehringer Ingelheim is supporting the ASCO Conquer Cancer Young Investigator Award, which brings our long—term partnership with ASCO to yet another level to support cancer research.
Please see below for the downloadable versions of the presentations from the congress related to our activities.
PK/PD properties of BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking Nanobody®, in patients (pts) with advanced/metastatic solid tumors (Poster #349)
Le Tourneau et al.
First-in-human phase I trial of BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking Nanobody®, given every 3 weeks (q3w) in patients (pts) with advanced/ metastatic solid tumors (Poster #137)
Le Tourneau et al.
Find out more about other oncology events
Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.
*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.
**This is an investigational compound and has not been approved. Its safety and efficacy have not been established.
© 2018 Boehringer Ingelheim International GmbH. All rights reserved.
Last updated: June 2018
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue